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Abstract
The ICL1 gene, which encodes the glyoxylate cycle enzyme isocitrate lyase (Icl1), is re‐
quired for the growth of Candida albicans on non-fermentable carbon sources and for this
yeast to be virulent. The aim of this study is to test the stability of the Icl1 enzyme in re‐
sponse to glucose. Glucose was found to trigger the degradation of the ICL1 but the
CaIcl1 was not destabilized by glucose. When CaIcl1 was expressed in Saccharomycess cer‐
evisiae, it was not degraded in response to glucose, suggesting that CaIcl1 has lost the mo‐
lecular signal that triggers destabilization in response to glucose. However, when ScIcl1
was expressed in C. albicans it was rapidly degraded in response to glucose indicating
that C. albicans has retained the molecular apparatus for glucose-accelerated degradation
of target proteins. ScIcl1 degradation was slowed in Caubi4/ubi4 in which ubiquitin-medi‐
ated protein turnover is reduced. Furthermore, the addition of putative ubiquitination
site to the carboxyl-terminus of CaIcl1 led to the glucose-accelerated degradation of this
protein. C. albicans has retained the apparatus for ubiquitin-mediated degradation of tar‐
get protein in response to glucose. However, CaIcl1 has lost the Ubi-site that mediate glu‐
cose accelerated protein degradation, thereby allowing C. albicans to simultaneously
assimilate alternative carbon sources and glucose.
Keywords: Glyoxylate cycle, isocitrate lyase (Icl1), metabolic adaptation, virulence, path‐
ogenicity
1. Introduction
Candida albicans is a major fungal pathogen of humans causes superficial and deep-seated
candidiasis infections [1, 2]. C. albicans is an opportunistic pathogen residing as a commensal
in the oral cavity and gastrointestinal and urogenital tracts of many individuals [3, 4]. The
severity of candidiasis ranges from superficial mucosal infections to systemic or disseminated
infections. In healthy individuals, C. albicans is relatively harmless. However, immunocom‐
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promised patients can get disseminated candidiasis in deep tissues that are difficult to
diagnose and can result in death [5, 6].Treatment involves the use of antifungals such as
fluconazole, amphotericin B and caspofungin [7, 8]. However, these treatments are not always
successful [9].
This chapter addresses the metabolic adaptation of isocitrate lyase (ICL1) of this fungal
pathogen in humans. This topic is important for studying the pathogenicity of C. albicans
because this medically important fungus must grow to cause infections, and to grow it must
assimilate carbon. C. albicans can occupy various diverse niches in humans, and many of these
niches contain a range of different carbon sources. The question arises whether this pathogen
is able to exploit this range of carbon sources if glucose happens to be present. This would not
be the case in the model yeast Saccharomycess cerevisiae because various forms of glucose
regulation inhibit the assimilation of alternative carbon sources in this model yeast [10 - 13].
Therefore, this first compares the impact of glucose on the assimilation of alternative carbon
sources in these two yeasts and then examines whether molecular mechanisms exist in C.
albicans to promote the rapid turnover of target proteins in response to glucose. Hence, this
section focusses on commensalism, C. albicans infections, and antifungal therapies.
Candida infections have been reported for virtually every tissue of the human body, and they
can be classified according to different criteria [14]. Superficial infections affect the skin and
mucous membranes [15]. In contrast, invasive candidiases include candidemia, acute or
chronic haematogenously disseminated candidiasis (infections of the bloodstream), and deep-
seated infections of the internal organs [16].
C. albicans has evolved to become an effective commensal organism [17]. In the state of
commensalism, Candida species live as relatively harmless members of the microflora of
healthy individuals causing no discernible disease. Candida species are “carried” in the oral
cavity, the GI tract, the anus and groin of healthy individuals, and also in the vaginal canal
and vulva of healthy women [14, 18]. Candida is carried by the most of healthy individuals and
can attain surprisingly high densities without symptoms of disease [19]. C. albicans is found in
stools of about 50% healthy people in addition to the many bacteria that usually inhabit the
GI tract [20]. The proliferation of pathogenic microorganisms such as Candida is inhibited partly
by the growth of harmless bacteria in these niches [21]. The symbiosis of these microorganisms
depends on the amount of mucus, the peristaltic behaviour of the bowel and the presence of
specific host antibodies and on the capacity of these microbes to adhere to epithelial cells [20].
C. albicans is the most virulent Candida species; among the Candida species, C. albicans is the
most commonly isolated yeasts from susceptible hosts [22 - 24]. Multiple risk factors play a
role in increasing likelihood of C. albicans undergoing the transition from harmless commensal
to a virulent pathogen. These risk factors include injuries or traumatic surgery; the presence
of indwelling devices, such as catheters or prosthetic devices; antibiotic treatment, which
reduces the competitiveness of bacterial species in host niches; and age, with new born babies
or aged individuals displaying increased risk of infection [14, 24, 25].
Candidemia is defined as the isolation of Candida from at least one blood culture specimen.
This type of infection is mainly acquired as the result of neutropenia, injuries caused by recent
surgery or the presence of indwelling devices. Also the use of broad-spectrum antibiotics
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represents another significant risk factor [16]. Candida not only often infects the livers of
patients during systemic candidiasis but can also thrive in their spleen, brain or kidney [26].
C. albicans skin infections mostly occur in warm and moist niches such as the armpit, the
perineum and skin folds. Similarly, Candida is a common cause of nappy (diaper) rash in
infants, and it particularly affects obese and elderly adults, as well as the inframammary region
of women. Itching and burning are the common symptoms of these types of infections [15].
Most women suffer from oral and vaginal infections (thrush) at least once in their life time [27].
Also, HIV and AIDS -patients suffered from oral thrush before the advent of the highly active
anti-retroviral treatment (HAART), which includes a protease inhibitor that also inhibits an
important virulence attribute of C. albicans- secreted aspartyl protease [28].
There are three main classes of clinically useful antifungal drugs: the polyenes, the azoles and
the echinocandins. Amphotericin B is the main drug in the polyene family. It is thought to
perturb the functionality of the fungal plasma membrane via interactions with ergosterol [29].
Unfortunately, the clinical utility of Amphotericin B is limited because it can cause nephro‐
toxicity in patients.
The azoles are an expanding family of compounds, as exemplified by the classic drug flucoa‐
zole. They target ergosterol synthesis, and hence the fungal plasma membrane [29]. Additional
antifungal agents are being developed. These include triazoles such as posaconazole, ravuco‐
nazole and voriconazole. This strengthens the choice of azoles, which is the most successful
antifungal class in the clinic since the late 1960s. Voriconazole is a broad spectrum drug that
is fungicidal against some isolates of filamentous species [30]. Posaconazole also inhibits a
broad spectrum of fungi, and has shown promising effects against Coccidioides in preclinical
studies [31]. Meanwhile, ravuconazole has a long plasma half-life in humans that might
improve its efficacy [32].
Echinocandins such as caspofungin, anidulafungin and micafungin target cell wall β-1 3-
glucan synthesis [29]. The development of echinocandins represented a major advance in
antifungal drug development because they targeted a new area of fungal cell biology -the cell
wall [29]. C. albicans cells can become tolerant to echinocandin treatment via activation of the
cell wall rescue pathway leading to elevated chitin synthesis [33].
2. Effect of glucose on alternative carbon sources in Candida albicans
The assimilation of carbon sources is fundamentally important for the growth of C. albicans
and for the establishment of infections in the human host. As described earlier, to grow, a
microbe must be able to assimilate carbon [34]. For most yeasts, glucose is generally a preferred
carbon source and for S. cerevisiae the chosen mode of metabolism is often fermentative in the
presence of excess glucose. This uses the Embden-Meyerhof or glycolytic pathway, resulting
in the formation of ethanol. In the absence of glucose, S. cerevisiae adapts to utilise the alter‐
native carbon sources that are available and switching to non-fermentable carbon metabolism.
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Likewise, C. albicans alters the expression of its metabolic functions to facilitate cell survival
[35]. C. albicans adjusts its metabolism to growth in biofilms by up-regulating amino acid
biosynthesis genes [36]. When exposed to human neutrophils or cultured macrophages, C.
albicans also up-regulates amino acid biosynthesis genes and displays a shift from fermentative
to non-fermentative metabolism [35, 37, 38]. Importantly, the utilisation of non-fermentable
carbon sources requires gluconeogenesis and the glyoxylate cycle [39]. Furthermore, the
glyoxylate cycle is required for fungal virulence [40]. These examples illustrate the metabolic
flexibility of this pathogen and the relevance of metabolic adaptation pathogenicity [41].
Our understanding of the physiology of C. albicans has been largely based on presumptions
that the central carbon metabolism in S. cerevisiae and C. albicans is similar. In these fungi, the
pathways of central carbon metabolism, including glycolysis, gluconeogenesis, the pentose
phosphate pathway, the tricarboxylic acid (TCA) cycle and glyoxylate cycle, are highly
conserved [14, 42]. However, metabolic differences do exist between C. albicans and S.
cerevisiae, the most obvious of which relates to their patterns of sugar utilisation [41]. For
example, S. cerevisiae belongs to the group that is called Crabtree-positive yeasts which have
the ability to produce ethanol even in the presence of oxygen. In contrast, C. albicans is
designated as a Crabtree-negative yeast [43] because it retains respiratory capacity in the
presence of excess glucose [44].
As described earlier, pathways of alternative carbon assimilation in S. cerevisiae are subject of
glucose repression study. The genetics of glucose repression have been studied, and the
regulatory elements that drive this regulation have been described in S. cerevisiae [10, 12, 45,
46, 47]. These include co-regulatory mechanisms that act on common elements within the
promoter sequences of gluconeogenic and glyoxylate cycle genes. The carbon source regulator
elements (CSRE) in the promoters of the S. cerevisiae PCK1, FBP1, MLS1 and ACR1 are required
for their transcriptional induction in the absence of glucose [48 - 52]. In addition the promoters
of the S. cerevisiae ICL1, MLS1 and FBP1 genes contain binding sites for the transcription
repressor Mig1 [53]. Mig1 represses the transcription of these genes in the presence of glucose,
and the activity of Mig1 is being regulated by Snf1 (AMP kinase) signalling.
Transcript profiling of glucose responses in C. albicans and S. cerevisiae has shown that both
yeasts are sensitive to very low levels of glucose [54, 55]. In S. cerevisiae and C. albicans, glycolytic
genes were up-regulated and gluconeogenic and TCA cycle genes were down-regulated even
when only 0.01% glucose was added to the growth medium. Yin et al. [54] also showed that
S. cerevisiae ribosomal protein genes also respond to glucose but that they were less sensitive
to glucose than the metabolic genes mentioned above. In S. cerevisiae, ribosomal protein gene
expression was up-regulated following glucose addition at concentrations above 0.1% [54, 56].
Therefore addition of glucose to S. cerevisiae cells growing on alternative carbon sources causes
a rapid shift from non-fermentative to fermentative metabolism, in part through tight regula‐
tion of gene transcription. Glucose also regulates metabolic activity in S. cerevisiae at post-
transcriptional levels. Glucose triggers the accelerated decay of gluconeogenic mRNA (PCK1,
FBP1) [54]. Furthermore, glucose triggers the catabolite inactivation and degradation of
gluconeogenic and glyoxylate cycle enzymes in S. cerevisiae. Fructose-1,6-bisphophatase
(FBPase) is expressed when yeast cells are grown on non-fermentable carbon sources. When
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the cells are then transferred to a glucose-containing medium, the cells rapidly degrade FBPase
to inactivate gluconeogenic activity. This was shown by immunoprecipitation and Western
blotting [57]. These authors found that the ubiquitin-conjugating enzyme Ubc8p contributes
to glucose-induced ubiquitination of FBPase and that this ubiquitination proceeds the
catabolite degradation of the enzyme via the proteasome [58], three other gluconeogenic and
glyoxylate cycle enzymes were identified as additional targets of the catabolite inactivation
machinery [59]. In addition, it was discovered that an amino-terminal proline residue is
essential for the rapid degradation of FBPase in response to glucose. FBPase phosphorylation
was not necessary for degradation to occur [59]. This amino-terminal ubiquitination target site
on FBPase essentially functions as an autonomous, primary degradation signal.
We reasoned that glucose responses might have diverged significantly between C. albicans and
S. cerevisiae. Our rationale was that the relaxation of glucose repression would confer an
evolutionary advantage upon a yeast such as C. albicans by allowing this pathogen to continue
to assimilate alternative carbon sources even when small amounts of glucose are present in
vivo. This section describes the testing of this working hypothesis through comparison of the
effects of glucose upon gluconeogenic and glyoxylate cycle gene expression in C. albicans and
S. cerevisiae.
To understand carbon assimilation in C. albicans, growth on selected alternative carbon sources
was first defined. Therefore analogous growth experiments were carried out for both S.
cerevisiae and C. albicans in media containing glucose or alternative carbon sources. Lactic acid
was chosen as one alternative carbon source because it is a three-carbon molecule of physio‐
logical relevance found in various host niches and in the bloodstream after exercise [60]. Also
Aberdeen Fungal Group Laboratory has generated a considerable body of data on cells grown
on lactate [54, 55].
Yeast cells were grown overnight in media containing 2% lactate or 2% (2% each or 1% + 1%)
both glucose and lactate. These cells were then harvested and used to inoculate fresh media
of the same composition and grown for 10 hours. Glucose and ethanol levels and growth
absorbance (at OD340) were measured.
As expected, both yeasts grew better on media containing glucose plus lactate, than on lactate
alone. C. albicans grew faster than S. cerevisiae on both media under these conditions. However,
both yeasts displayed similar rates of glucose consumption and different ethanol accumulation
under these conditions. Glucose was utilised rapidly by both S. cerevisiae and C. albicans.
Ethanol levels in glucose plus lactate cultures significantly increased in S. cerevisiae, but they
remained similar during glucose assimilation by C. albicans. This indicated that most glucose
was not fermented to ethanol under the experimental conditions examined in C. albicans
(minimal medium; 30°C; 200 rpm).
The fatty acid i.e. oleic acid was chosen as the second alternative carbon source for analysis. A
fatty acid was chosen because lipids represent a rich source of carbon in the host, C. albicans is
known to secrete lipases [61], and C. albicans is known to induce fatty acid β-oxidation genes
following phagocytosis by macrophages [62].
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Once again, analogous growth experiments were carried out for both S. cerevisiae and C.
albicans in media containing oleic acid or glucose plus oleic acid. Yeasts cells were grown
overnight in media containing 0.2% oleic acid or 2% glucose plus oleic acid, and these cells
were used to inoculate fresh media containing the same amount of carbon sources. Growth
was monitored for 10 hours. Once again, glucose and ethanol levels and absorbance (OD340)
were measured.
Both yeasts grew on oleic acid or on oleic acid plus glucose. As expected more growth was
observed for both yeasts on the glucose containing medium compared with the medium
containing oleic acid alone. C. albicans grew more efficiently than S. cerevisiae on both media.
Once again, the rates of glucose consumption and ethanol production were different for both
yeasts. Both yeasts consumed glucose rapidly, but ethanol levels were accumulated signifi‐
cantly throughout the experiment in S. cerevisiae. This suggested that most glucose was not
fermented to ethanol under these conditions in C. albicans. Less ethanol was generated during
growth on oleic acid (about 2 mg/ml or 0.02%) compared to during growth on lactic acid (about
4 mg/ml or 0.04%).
Previous work by Yin et al. [54] using Northern blotting and transcriptomic analyses showed
that transcripts encoding the gluconeogenic enzymes (FBP1 and PCK1) are repressed by
glucose in S. cerevisiae. To reconfirm this report and to compare it with the glucose responses
of C. albicans more directly in this study, we first examined the responses of S. cerevisiae
glyoxylate cycle (ScICL1) and gluconeogenic mRNAs (ScPCK1) using the following experi‐
mental approach.
S. cerevisiae cells were grown to mid-exponential phase in a minimal medium containing lactate
or oleic acid as the sole carbon source and lactate + glucose and oleic acid + glucose. The levels
of the S. cerevisiae ICL1 and PCK1 mRNAs were measured relative to the housekeeping β-actin
gene (ScACT1), following the addition of glucose to a final concentration of 2%. Samples were
collected and frozen immediately in liquid nitrogen for RNA extraction. S. cerevisiae ICL1,
PCK1 and ACT1 primers [63] were then designed, and the expression of these genes was
quantified using Syber green quantitative real-time polymerase chain reaction (qRT-PCR).
ScICL1 mRNA levels showed a dramatic decrease within 30 minutes of glucose addition to
cells growing on lactate or oleic acid. Similarly, ScPCK1 mRNA levels declined after glucose
addition to cells growing on lactate or oleic acid media. This strong repression occurred 30
minutes after glucose addition. These results confirmed that in S. cerevisiae, the ICL1 and PCK1
transcripts are strongly repressed by glucose [54]. At least for the PCK1 mRNA, this repression
is mediated by transcriptional repression and accelerated mRNA degradation [54].
Aberdeen Fungal Group Laboratory has also described the global transcriptional responses of
C. albicans to low (0.01%), medium (0.1%) and high (1%) glucose concentrations by microarray
analysis [55]. The data indicated that a total of 347 C. albicans genes were up-regulated, and
344 genes were down-regulated in response to at least one of the glucose concentrations
examined. There are170 of these genes that were up-regulated and 180 genes that were down-
regulated by 0.01% glucose, indicating that about half of glucose-regulated genes are respon‐
sive to low glucose levels. Therefore, the authors concluded that like S. cerevisiae, C. albicans is
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exquisitely sensitive to glucose, responding to concentrations as low as 0.01%. Hence, at the
start of this study, an aim was to confirm the impact of glucose on specific mRNAs that encode
enzymes required for the assimilation of alternative carbon sources. The transcripts encoding
the glyoxylate cycle enzyme isocitrate lyase (CaICL1) and the gluconeogenic enzyme phos‐
phoenolpyruvate carboxykinase (CaPCK1) were the main focus here.
C. albicans cells were grown to mid-exponential phase in media containing lactate or oleic acid
as the sole carbon source using the same procedures described for S. cerevisiae by Yin et al. [54].
Glucose was then added to a final concentration of 2%; samples were taken for RNA analysis
at various times thereafter; the levels of the CaICL1, CaPCK1 and CaACT1 mRNAs were
measured by qRT-PCR. The relative expression of CaICL1 (compared with the internal CaACT1
control) was high in lactate- and oleic acid-grown cells compared with the cells that were
exposed to glucose. The CaICL1 mRNA was strongly down-regulated within 60 minutes after
glucose addition under both of these growth conditions. The CaPCK1 mRNA was expressed
at relatively high levels in lactate- and oleic acid-grown cells, and was also strongly down-
regulated within 60 minutes of glucose addition. These results confirmed that in both S.
cerevisiae and C. albicans, the ICL1 and PCK1 genes are strongly repressed by glucose [63].
The next step is to test the effects of glucose on the expression levels of the CaIcl1 and CaPck1
proteins in C. albicans and to compare this response with the corresponding situation S.
cerevisiae. In S. cerevisiae, the effects of glucose on fructose-1,6-bisphosphatase (FBPase) have
been intensively studied and it was reported that the FBPase protein (ScFbp1) is rapidly
degraded upon the addition of glucose [58]. Also it has been reported that the levels of cytosolic
malate dehydrogenase, fructose-1,6-bisphosphatase, isocitrate lyase and phosphoenolpyru‐
vate carboxykinase are all low in S. cerevisiae after glucose addition [59]. Therefore, as a starting
point, we tested for ourselves whether Icl1 and Pck1 decline in S. cerevisiae upon glucose
addition.
To achieve this, the S. cerevisiae ICL1 coding region was tagged at its 3´-end with Myc9 and the
PCK1 coding region was tagged with HA6. Control Western blots with these tagged strains
and their untagged parental strains demonstrated that ScIcl1-Myc9 and ScPck1-HA6 were
expressed during growth on non-fermentable carbon sources [63].
After confirming the validity of the ScIcl1-Myc9 and ScPck1-HA6 tagging, the next step is to
examine the effects of glucose upon the stability of these proteins following glucose addition
to S. cerevisiae cells. Therefore, the epitope-tagged S. cerevisiae strains were grown on lactate or
oleic acid, and then glucose was added to a final concentration of 2%. All experiments were
performed on exponentially growing cells. Samples were prepared at various times thereafter,
and the levels of the ScIcl1-Myc9 and ScPck1-HA6 proteins were measured by Western blotting.
Clearly, glucose addition led to the degradation of ScIcl1 and ScPck1. These results confirmed
that in S. cerevisiae Icl1 and Pck1 are degraded in response to glucose. Interestingly, the
degradation of ScPck1 appears to start about 2 hours after glucose addition, whereas ScIcl1
degradation starts earlier. This might reflect differences in the mechanisms of glucose-
activated degradation of these proteins, via ubiquitin-mediated or vacuole-mediated path‐
ways, as described by Regelmann et al. [64].
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Having confirmed that glucose addition to cells growing on non-fermentable carbon sources
leads to the degradation of Icl1 and Pck1 in S. cerevisiae, the next step is to test the effects of
glucose upon the corresponding enzymes in C. albicans.
C. albicans strains expressing Myc3-tagged Icl1 or Myc3-tagged Pck1 were then used in an
analogous experimental design to our previous S. cerevisiae protein analysis. C. albicans cells
were grown in media containing non-fermentable carbon sources (lactate or oleic acid) as sole
carbon sources, and then 2% glucose was added while cells were in the exponential growth
phase. Cells were then harvested at various time periods, and their proteins were extracted
for Western blotting. Proteins were loaded in equal amounts onto the SDS/PAGE gels, and
expression of the Myc3-tagged CaIcl1 and CaPck1 proteins was detected with anti-Myc
antibodies and the images quantified using a phosphorimager.
The C. albicans Icl1 protein was expressed during growth on lactate or oleic acid. Interestingly,
CaIcl1 was not destabilised by the addition of 2% glucose. Indeed, CaIcl1 protein levels were
not significantly different from the control even after 4 hours. Likewise, CaPck1 expression
levels were relatively high during growth on lactate or oleic acid, and CaPck1 was also not
destabilised by glucose addition. These data suggested that glucose does not affect the stability
of the CaIcl1 and CaPck1 proteins. This behaviour of C. albicans was in direct contrast to that
observed in S. cerevisiae, in which the Icl1 and Pck1 proteins were destabilised by glucose [63].
Carbon assimilation is essential for the generation of new biomass (i.e. growth). Therefore, the
growth of C. albicans in the immunocompromised host depends upon the assimilation of
available carbon sources in vivo, and the fungus must adjust its metabolism to the microen‐
vironments it occupies in the host [41].
Previous reports have suggested that S. cerevisiae might provide a reasonable metabolic
paradigm for C. albicans as reviewed by Brown [41]. Certainly, many of the pathways of central
metabolism are conserved in fungi, including the glycolytic, gluconeogenic and pentose
phosphate pathways and the TCA and glyoxylate cycles [14, 42]. Pathways for the generation
of storage and cell wall carbohydrates are also conserved. Furthermore, the pathways of amino
acid, lipid and nucleotide catabolism and anabolism appear to be conserved. However,
significant metabolic differences do exist between C. albicans and S. cerevisiae, as revealed by
their different patterns of sugar utilisation. In fact, differences in the patterns of carbohydrate
assimilation are used routinely to distinguish C. albicans from other microbes in the clinic [65,
66]. Also, significant differences in the regulation of carbon metabolism are emerging for C.
albicans and S. cerevisiae [67, 68]. Based on these observations, we tested whether there are
metabolic differences in carbon assimilation between these fungi. The approach here was to
measure the effects of glucose upon the assimilation by S. cerevisiae and C. albicans of radiola‐
belled lactic or oleic acid into large molecular weight compounds.
To achieve this, S. cerevisiae cells were grown to exponential phase on media containing lactate
or oleic acid as sole carbon source. These cells were then harvested and resuspended in
equivalent media containing radiolabelled lactic or oleic acid. Glucose (2%) was added to test
samples, and no glucose was added to control samples. The assimilation of 14C-lactic acid or
3H-oleic acid by S. cerevisiae cells into large molecular weight TCA-precipitable material was
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then measured. In S. cerevisiae, both lactate and oleic acid assimilation were rapidly repressed
by glucose. Therefore the S. cerevisiae cells stopped the assimilation of these secondary carbon
sources and apparently switched quickly to glucose assimilation. This confirmed the generally
held view that S. cerevisiae does not assimilate both glucose and secondary carbon sources at
the same time.
The next step is to investigate the effects of glucose on carbon assimilation in C. albicans. Once
again, the approach was to test the assimilation of radiolabelled carbon sources by the cell. The
same procedures were followed as for S. cerevisiae, with C. albicans cells being grown on lactate
or oleic acid and then the assimilation of 14C-lactic acid or 3H-oleic acid into TCA-precipitable
material was measured after glucose addition [63].
Unlike S. cerevisiae, C. albicans was still able to assimilate both lactate and oleic acid for some
hours after addition of glucose. Lactate metabolism appeared to continue relatively normal
because only minor effects were observed in the lactate uptake following glucose addition.
Tests with the other secondary carbon source (oleic acid) showed similar results. Therefore,
C. albicans is able to assimilate lactate and glucose at the same time. Similarly, both oleic acid
and glucose can be assimilated by C. albicans at the same time. This suggests that glucose has
a minimal immediate impact on the ability of C. albicans to assimilate secondary carbon sources
at least over the timescales examined [63].
Therefore, there are significant differences between C. albicans and S. cerevisiae with respect to
the regulation of their assimilation of alternative carbon sources. Apparently in S. cerevisiae,
glucose and secondary carbon sources are not assimilated at the same time. In contrast, in C.
albicans, the continued stability of gluconeogenic and glyoxylate cycle enzymes after glucose
exposure correlates with the ability of C. albicans cells to continue to assimilate alternative
carbon sources, even after glucose addition. Hence, the hypothesis that significant metabolic
differences exist between C. albicans and S. cerevisiae was confirmed [63].
3. Glucose-accelerated protein degradation in Candida albicans
The previous section examined the impact of glucose on Pck1 and Icl1 expression and the
assimilation of alternative carbon sources such as lactic and oleic acid in C. albicans. So far, the
author’s data confirmed that transcript profiling results were described by Yin et al. [54] and
Rodaki et al. [55]. Numerous S. cerevisiae transcripts, including those encoding gluconeogenic
enzymes (FBP1 and PCK1), are repressed by glucose [54]. Similarly, 180 genes in C. albicans,
including gluconeogenic and glyoxylate cycle enzymes were, down-regulated, even in
response to very low concentrations of glucose (0.01%) [55]. The results presented in the
previous section confirmed that the ScICL1 and ScPCK1 genes in S. cerevisiae and the CaICL1
and CaPCK1 genes in C. albicans are exquisitely sensitive to glucose.
While S. cerevisiae and C. albicans displayed similar responses at the transcriptional level, they
diverged significantly at the post-transcriptional and metabolic levels. The C. albicans Icl1 and
Pck1 enzymes were expressed during growth on lactate and oleic acid and were not destabi‐
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lised by the addition of 2% glucose. In contrast, their orthologues in S. cerevisiae were rapidly
destabilised by glucose. Consequently, this appeared to affect carbon assimilation, allowing
C. albicans to continue to assimilate alternative carbon sources even after exposure to glucose.
In contrast, following glucose addition to S. cerevisiae cells, Icl1 and Pck1 were degraded and
the cells stopped assimilating lactic acid or oleic acid. These new findings showed that there
are fundamental differences in the regulation of carbon assimilation in C. albicans compared
to S. cerevisiae [63]. The next step is to examine the basis for these differences and in particular,
possible differences in glucose-accelerated protein degradation between C. albicans and S.
cerevisiae. The focus of these studies was on Icl1.
Entian and Schüller [46] reported the genetic characterisation of C. albicans gluconeogenic and
glyoxylate cycle genes. The C. albicans FBP1, PCK1, MLS1 and ICL1 genes were all isolated by
functional complementation of the corresponding S. cerevisiae deletion mutants. Remarkably,
the regulation of the heterologously expressed C. albicans gluconeogenic and glyoxylate cycle
genes in S. cerevisiae was similar to that of their S. cerevisiae orthologues. Therefore, in this
project we expressed C. albicans ICL1 in S. cerevisiae and tested whether CaIcl1 is destabilised
by glucose in S. cerevisiae. The other aims of this section are to test whether C. albicans has
retained the ability to destabilise target proteins in response to glucose and to examine the
signals and mechanisms that trigger glucose-mediated destabilisation of target proteins in C.
albicans.
To test whether C. albicans is able to degrade proteins in response to glucose, the S. cerevisiae
ICL1 gene was expressed in C. albicans. To achieve this, one C. albicans ICL1 allele was replaced
with a tagged S. cerevisiae ICL1 ORF. The ScICL1 locus in S. cerevisiae was first tagged using
primers with Myc3-URA3, and the genomic DNA from this tagged was PCR amplified using
primers to create the CaICL1p-ScICL1-MYC3-URA3 cassette [63]. This cassette was transformed
into the CaICL1 locus in C. albicans ICL1/ICL1. Before going further, it was necessary to test
whether the ScICL1-MYC3-URA3 sequence was integrated accurately into the CaICL1 genomic
locus. Three primer pairs were designed to amplify overlapping fragments of the CaICL1p-
ScICL1-MYC3-URA3 locus based on the in silico sequence [63]. PCR amplification using these
primers yielded the desired bands, establishing that the newly created strain ScICL1-MYC3-
URA3 sequence had integrated correctly into the CaICL1 locus in the C. albicans genome [63].
Then Western blots were performed to test whether the ScIcl1-Myc3 protein was detectable in
these C. albicans transformants. The two positive clones were grown to stationary phase
overnight on an alternative carbon source in the absence of glucose. Controls were included
to confirm expression of the tagged ScIcl1 in C. albicans. In both new strains, an Icl1 band of
the predicted size (62 kDa) was observed, which was the right size compared to the controls.
To further ensure the correct replacement of the C. albicans ICL1 ORF with the tagged S.
cerevisiae ICL1 ORF, the functionality of this ScICL1 ORF was tested in C. albicans. The ScICL1-
MYC3-URA3 cassette was amplified from genomic DNA and transformed into C. albicans ICL1/
icl1 cells selecting heterozygote for uridine prototrophs. Once again, correct insertion of the
ScICL1-MYC3-URA3 sequence was confirmed by diagnostic PCR using the three primer pairs
as before and also tested by another three primer pairs to confirm the construction of the C.
albicans ScICL1-MYC3-URA3/icl1 strain [63].
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Western blots were performed to confirm the expression of the Myc-tagged ScICL1 ORF S.
cerevisiae in C. albicans ScICL1-MYC3-URA3/icl1 background. Two positive clones were grown
to stationary phase on lactate-containing medium and protein subjected to Western blotting.
This showed the expression of the tagged ScIcl1 of about 62 kDa in C. albicans. As expected the
ScIcl1 protein was not expressed during growth on glucose because it was expressed from the
endogenous CaICL1 promoter that is glucose repressed [63].
The phenotype of this C. albicans ScICL1-MYC3-URA3/icl1 mutant was then tested by growing
in different carbon sources: glucose, fructose, lactate, oleic acid, pyruvate and acetate. The
mutants were compared with control C. albicans ICL1/ICL1, ICl1/icl1 and icl1/icl1 strains. The
presence of the ScICL1 gene in a C. albicans icl1 background was sufficient to restore growth
on lactate, oleic acid, pyruvate and acetate. This growth was comparable to the positive ICL1/
ICL1 control strain and contrasted with the negative icl1/icl1 control, which was only able to
grow on glucose and fructose. This indicated that the tagged ScICL1 was functional in C.
albicans [63].
Having confirmed the genotype, expression and functionality of the ScICL1 ORF in C.
albicans, the next step was to test the effects of glucose on the levels of the ScIcl1 protein when
expressed in C. albicans. The C. albicans ScICL1-MYC3-URA3//icl1 strain was first grown on
alternative carbon sources (lactate or oleic acid), and then glucose was added to a final
concentration of 2%. Samples were then taken at regular intervals, proteins extracted, and
ScIcl1-Myc3 levels examined by Western blotting. Control cultures to which no glucose was
added, were also examined. This showed that ScIcl1 levels remained high in C. albicans cells
grown on the alternative carbon sources. However, following the addition of 2% glucose to C.
albicans cells, ScIcl1 was degraded. This indicates that C. albicans has retained the capacity to
destabilise target proteins in response to glucose [63].
C. albicans is clearly capable of degrading target proteins following exposure to glucose.
Therefore, why is CaIcl1 not degraded following glucose addition? Has CaIcl1 lost the specific
signal that would target it for glucose-accelerated degradation? To test this, the CaIcl1 protein
was expressed in S. cerevisiae.
To achieve this, the S. cerevisiae ICL1 ORF was replaced with a Myc3-tagged C. albicans ICL1
ORF. The C. albicans ICL1-MYC3-URA3 was PCR amplified using the primers and transformed
into S. cerevisiae strain (Ura-, Leu-) selecting for uracil prototrophs. Correct integration of the
CaICL1-MYC3-URA3 cassette into the ScICL1 locus was confirmed by diagnostic PCR using
three primer pairs. In this way, a new S. cerevisiae strain was constructed containing a ScICL1p-
CaICL1-MYC3-URA3 mutation [63].
Western blots were performed to test whether the CaIcl1-Myc3 protein of the predicted 61 kDa
size was expressed in S. cerevisiae. Cells were grown on alternative carbon sources in the
absence of glucose and compared to positive and negative controls. These Western blots
confirmed that CaIcl1 61 kDa was expressed in S. cerevisiae during growth on lactate or oleic
acid and that CaIcl1-Myc3 was in the correct size compared to the positive control in which
CaIcl1-Myc3 was expressed in C. albicans. Interestingly, CaIcl1-Myc3 was expressed in S.
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cerevisiae cells grown on lactate or oleic acid, but not in cells grown on glucose. This was to be
expected when the CaICL1-MYC3 ORF was expressed from the ScICL1 promoter [63].
Having confirmed the genotype of the S. cerevisiae mutant expressing the C. albicans ICL1 ORF,
the next step was to test the effects of glucose on the CaIcl1-Myc3 protein levels in S. cerevi‐
siae. The S. cerevisiae strain was grown on lactate or oleic acid, and then glucose was added to
a final concentration of 2%. Cells were harvested at various time periods thereafter, protein
extracts prepared, and CaIcl1-Myc3 protein levels measured by Western blotting. The results
showed that CaIcl1-Myc3 remained at high levels in S. cerevisiae during growth on the alter‐
native carbon sources. Even upon the addition of 2% glucose, the levels of CaIcl1-Myc3
remained high in S. cerevisiae. Minimal decay of the CaIcl1-Myc3 protein was observed even 4
hours after glucose addition. These data suggest that the C. albicans Icl1 protein has lost the
signals that trigger destabilisation in response to glucose [63].
The above work suggested that C. albicans has retained the ability to degrade target proteins
in response to glucose, but that CaIcl1 has lost the specific signal(s) that trigger this glucose-
accelerated protein degradation. What is the nature of this degradation signal that has been
lost by CaIcl1?
Ubiquitination is known to play a role in the glucose-accelerated degradation of gluconeogenic
enzymes in S. cerevisiae [57]. Previously, Entian and Barnett [45] demonstrated that Ubc8
functions in the catabolite degradation of fructose-1,6-bisphosphatase in S. cerevisiae. Earlier,
Johnson et al. [69] showed that ubiquitin acts as a degradation signal in S. cerevisiae. Therefore,
consensus ubiquitination target sites were examined in CaIcl1 and ScIcl1 using Ubpred
(Predictor of protein ubiquitination site, from htt/www.ubpred.org/index.html) [70 - 73].
Based on this bioinformatic comparison, the ScIcl1 sequence contains strong consensus
ubiquitination sites at amino acids 158 and 551, but there is a lack of high confidence ubiqui‐
tination targets in CaIcl1. This prediction was based on high level of confidence which is
described in Ubpred system containing score range 0.84 ≤ s ≤ 1.00, 0.197 for sensitivity and
0.989 for specificity. These included the hydrophobic nature of the ubiquitination target site
for the high confidence prediction (TEDQFKENGVKK), which is contrast to the low- and
medium- confidence sites that contain acidic and basic residues in the putative ubiquitination
site (NGVKK; FNWPKAMSVD) [70 - 73]. Therefore, the presence of consensus ubiquitination
sites in these proteins correlated with glucose-accelerated degradation.
Hence, the next step is to test whether ScIcl1 decay rates in C. albicans are affected by inacti‐
vation of polyubiquitin (UBI4).
To achieve this, the experimental goal was to introduce the Myc3-tagged S. cerevisiae ICL1 ORF
into a C. albicans ubi4/ubi4 mutant [74]. The ScICL1-MYC3-URA3 cassette was PCR amplified
using primers and transformed into C. albicans ubi4/ubi4 cells selecting for uridine prototrophs.
The correct insertion of the ScICL1-MYC3-URA3 into the CaICL1 locus was confirmed by
diagnostic PCR with the same primer pairs as before. These amplified the conjoined sequence
of the CaICL1 promoter and the ScICL1 ORF. The successful and accurate insertion of the
ScICL1-MYC3-URA3 cassette into C. albicans ubi4/ubi4 mutant was confirmed in this way.
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Western blotting was then performed to test whether a ScIcl1-Myc3 protein of the predicted
size was expected in the ubi4/ubi4 cells. Cells were grown overnight on the alternative carbon
sources (lactate and oleic acid) in the absence of glucose. A new Myc3-containing protein of 62
kD was observed indicating that the ScIcl1-Myc3 protein was expressed on YPL and was the
right size [63].
Having confirmed the genotype and the expression of the ScICL1 ORF in C. albicans ubi4/
ubi4 cells, the next step was to test the effects of glucose on ScIcl1-Myc3 protein levels. The ubi4/
ubi4 cells were grown on lactate or oleic acid and then glucose was added to a final concen‐
tration of 2%. Interestingly, ScIcl1-Myc3 cells were more stable in C. albicans ubi4/ubi4 cells than
in wild type C. albicans cells after addition of 2% glucose. However, the inactivation of the UBI4
(polyubiquitination) locus did not completely inhibit the degradation of the ScIcl1-Myc3
protein such that it became as stable as ScIcl1-Myc3 in wild type C. albicans cells in the absence
of glucose. This might be because residual ubiquitination remains in ubi4/ubi4 cells thanks to
the presence of a second ubiquitin-encoding locus in C. albicans (UBI3) [74]. Nevertheless, it
was concluded that the inactivation of UBI4 (polyubiquitin) inhibits the glucose-accelerated
degradation of ScIcl1 in C. albicans. Ubiquitination plays a role in glucose-accelerated protein
decay in this fungus.
As stated above, ScIcl1 contains two high confidence putative ubiquitination sites located at
residues 551 and 158, whereas CaIcl1 contains no such sites. Therefore, we reasoned that if
ubiquitination plays a role in glucose-accelerated protein decay in C. albicans, then the addition
of a ubiquitination site to CaIcl1 would confer glucose-accelerated degradation upon this
protein. Therefore, the next experimental objective is to introduce the carboxyl-terminal
ubiquitin site from ScIcl1 (TEDQFKENGVKK) into CaIcl1, together with the Myc3 tag into wild
type polyubiquitin containing C. albicans cells [63].
To achieve this, a ScUBI-site-MYC3-URA3 cassette was PCR amplified from S. cerevisiae
genomic DNA and transformed into C. albicans ICL1/ICL1 cells. To confirm the correct
integration of this cassette at the 3´-end of the CaICL1 ORF in these cells, uridine prototrophic
transformants were subjected to diagnostic PCR using the same primer pairs as before and
new primer pairs. This PCR amplification yielded the desired bands, establishing that the
ScUBI-MYC3-URA3 was correctly integrated at the C. albicans ICL1 locus [63].
Having established the genotype of the new strain (C. albicans ICL1-ScUBI-site-MYC3-URA3),
the next step is to confirm the expression of the CaIcl1 protein carrying the carboxyl-terminal
ubiquitination site and the Myc3 tag. Therefore, Western blots were performed to test the
presence and size of the tagged protein. Five positive C. albicans clones were grown on an
alternative carbon source (lactate) in the absence of glucose, protein extracts were made, and
Western blots were performed, probing for the Myc epitope. A new Icl1-Myc3 band of about
61 kD was observed, confirming that the Icl1 protein was expressed on YPL and that it had a
similar size to the positive control ScIcl1-Myc3 [63].
Having confirmed the genotype of the new strain and the expression of the CaIcl1 protein with
the carboxyl-terminal ubiquitination site in C. albicans cells, the next step is to test the effects
of glucose on the stability of this protein. The new strain was grown on lactic or oleic acid and
glucose was added to a final concentration of 2%. Cells were harvested at various time periods
thereafter; protein was extracted and these were subjected to Western blotting. Interestingly
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the CaIcl1-Ubi-Myc3 protein was rapidly degraded following glucose addition to cells grown
on lactate or oleic acid. In conclusion, the addition of a ubiquitination site to CaIcl1 accelerates
its degradation in response to glucose in C. albicans [63].
The above observations strongly suggest that specific proteins can be targeted for degradation
in C. albicans following exposure to glucose, and these proteins are degraded via ubiquitina‐
tion. If this is the case, it should be theoretically possible to detect ubiquitinated forms of these
proteins. Hence immuno-precipitation experiments were then performed in an attempt to
demonstrate ubiquitinated forms of the CaIcl1-Myc3 protein in C. albicans. Proteins were
extracted from C. albicans ICL1-UBI-site-MYC3-URA3 cells 20, 40 and 120 minutes after glucose
addition. Analogous control extracts were also prepared from S. cerevisiae and C. albicans cells
expressing ScIcl1+Myc3, CaIcl1+Myc3 and untagged parental strains grown on lactate plus
glucose and lactate alone. These extracts were immunoprecipitated with an anti-Myc antibody
that was predicted to precipitate Icl1 proteins having carboxyl-terminal Myc3 tags. These
immunoprecipitates were then subjected to Western blotting with an anti-ubiquitin antibody
to test whether any of these Myc3-tagged Icl1 proteins carry ubiquitin sequences. The Western
blots were also probed with the anti-Myc antibody to confirm that Myc-tagged Icl1 proteins
had been immunoprecipitated. This was the case. Interestingly, a weak ubiquitin-containing
band of a length consistent with Icl1-Myc3 proteins was detected. Such bands were observed
in three replicate experiments. These weak bands were observed for the ScIcl1-Myc3 CaIcl1-
Ubi-Myc3 proteins following glucose addition (both proteins carry ubiquitination sites).
However, no ubiquitination of these proteins was observed in the absence of glucose, or for
the CaIcl1-Myc3 protein (which lacks a strong ubiquitination site) or for the untagged control
cells [63].
These data suggest that when S.cerevisiae Icl1 or an artificial C. albicans Icl1 carrying a ubiquiti‐
nation signal is expressed in C. albicans, it becomes ubiquitinated and destabilised in response
to glucose. However, the native C. albicans Icl1 protein is not destabilised by glucose. There‐
fore, in response to glucose, target proteins became ubiquitinated and then degraded in C.
albicans [63].
What natural C. albicans proteins might be subjected to ubiquitin-mediated, glucose-acceler‐
ated protein degradation? To address this, bioinformatic tools were used to predict possible
ubiquitination sites in glycolytic, gluconeogenic and glyoxylate cycle enzymes in S. cerevisiae
and C. albicans. Five enzymes were selected for analysis: Fbp1, Pck1, Mdh1, Eno1 and Mls1.
Based on this analysis, S. cerevisiae Fbp1, Pck1 and Eno1 appear to carry strong ubiquitination
sites, while only Eno1 C. albicans appears to have a high confidence ubiquitination site. In
conclusion, while these central metabolic pathways are highly conserved between S. cerevi‐
siae and C. albicans, these organisms appear to display significant differences in the presence
of ubiquitination sites in the orthologous enzymes [63].
4. Overview of Metabolic Adaptation in Candida albicans
A previous study suggested that C. albicans might be capable of using more than one carbon
source at the same time during growth in specific niches in the host [34]. This study was based
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on the analysis of specific promoter-green fluorescent protein (GFP) fusions during systemic
candidiasis. Almost all C. albicans cells infecting the kidney expressed GFP fusions with
glycolytic promoters (PYK1, PFK2). Meanwhile one third to one-half of cells infecting the
kidney also expressed ICL1- and PCK1-GFP fusions, suggesting that anabolic and catabolic
pathways might be expressed at the same time. If this is the case, in principle, this would allow
this pathogenic yeast to better utilise the complex mixture of available carbon sources in host
niches. This working hypothesis would be consistent with earlier studies, suggesting that C.
albicans is a glucose Crabtree-negative yeast. In other words, this pathogen retains respiratory
activity even following exposure to glucose [44]. During growth on glucose, ADH1 mRNA
levels rise to maximum levels during late exponential growth phase and then decline to low
levels in stationary phase [75]. The ADH1 mRNA is relatively abundant during growth on
galactose, glycerol, pyruvate, lactate or succinate, and less abundant during growth on glucose
or ethanol. However, alcohol dehydrogenase levels do not correlate closely with ADH1 mRNA
levels. This locus may be controlled at both transcriptional and post-transcriptional levels, or
other differentially regulated ADH loci may exist in C. albicans [75].
Interestingly, a significantly smaller proportion of glucose is fermented to ethanol by C.
albicans than by S. cerevisiae [75]. This is consistent with the low amounts of ethanol produced
by C. albicans observed in this study.
S. cerevisiae is not able to assimilate both non-fermentable carbon sources and glucose at the
same time because of glucose repression. Hence, we predicted that these yeasts have evolved
different responses to glucose. Therefore, in this study, I analysed the regulation of carbon
assimilation in C. albicans focussing on genes/enzymes involved in gluconeogenesis and the
glyoxylate cycle. I tested ICL1 and PCK1 gene expression, Icl1 and Pck1 protein stability and
the impact of glucose on the assimilation of non-fermentable carbon sources. The author
compared their C. albicans responses to those of S. cerevisiae under equivalent conditions. The
following conclusions can be drawn from these findings.
First, gluconeogenic and glyoxylate cycle mRNAs are sensitive to glucose in both C. albicans
and S. cerevisiae. This reconfirmed previous findings from Aberdeen Fungal Group Laboratory
[54, 55] and other laboratories [76]. Dramatic decreases in ICL1 and PCK1 mRNA levels were
observed in C. albicans cells after exposure to 2% glucose. This glucose concentration is higher
than the levels of glucose homeostatically maintained in human blood (about 0.1%). However,
it is already known that C. albicans responds to lower glucose concentrations within the
physiological range of blood glucose [54, 55]. Therefore, C. albicans is able to respond to blood
glucose levels during disseminated haematological infections. Interestingly, patients with
diabetes who often have elevated blood glucose levels, have a higher risk of systemic Candida
infections [14], and dietary glucose enhances C. albicans colonisation and invasion [77].
The second main observation was that the Icl1 and Pck1 proteins are stable in C. albicans
following glucose exposure. The addition of 2% glucose to C. albicans cells growing on lactate
or oleic acid did not trigger the degradation of the Icl1 and Pck1 proteins, at least within the 4
hours examined. This is in contrast to the situation in S. cerevisiae, where the addition of 2%
glucose triggered the rapid degradation of the Icl1 and Pck1 proteins. The estimated half-lives
for these proteins in S. cerevisiae are more than 20 hours [78] indicating that these proteins are
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very stable. This probably represents a significant difference in the physiological responses of
these pathogenic and benign yeasts to glucose. C. albicans is able to establish infections in
complex niches, many of which contain a rich mixture of alternative carbon sources [34]. The
stability of the Icl1 and Pck1 proteins in C. albicans, even in the presence of glucose, provided
the first clue that this pathogen might be able to assimilate alternative carbon sources at the
same time as glucose in these carbon-rich niches.
The third conclusion was that C. albicans is able to assimilate both glucose and alternative
carbon sources at the same time. It was shown that glucose addition has no major impact on
the assimilation of the alternative carbon sources (lactate and oleic acid). The maintenance of
gluconeogenic and glyoxylate cycle enzymes, therefore, appears to allow C. albicans to continue
to assimilate alternative carbon sources, even following glucose addition. Therefore, during a
transient exposure to glucose in the bloodstream, for example, C. albicans would be able to
maintain anabolic metabolism. Also, after phagocytosis, when the genes of glyoxylate cycle
and gluconeogenesis have been induced [34], these pathways probably remain active some
time afterwards because of the stability of their enzymes. It was reported that the glyoxylate
cycle helps to protect C. albicans against host anti-microbial defences by facilitating anabolic
metabolism in the absence of fermentable carbon sources [79]. Barelle et al. [34] indicated that
the pathogen C. albicans regulates central carbon metabolism in a niche-specific manner during
disease establishment and progression. These authors reported two stages C. albicans activate
the glyoxylate cycle and gluconeogenesis in response to phagocytosis during the early stage
of infection and this is followed by glycolytic metabolism when the fungus colonises tissue.
This metabolic flexibility is thought to increase the biological fitness of this pathogen within
its host. It is conceivable that the prolonged activity of the anabolic pathways might further
increase the fitness of this pathogen.
In conclusion, the regulation of central carbon metabolism in S. cerevisiae and C. albicans seems
to have evolved in ways that reflect their different biological niches. S. cerevisiae has adapted
to grow rapidly when high concentrations of sugars become available from fruit (from feasts to
famine) [10], whereas C. albicans appears to have adapted to utilise the complex mixtures of
carbon sources that are available in the GI tract or the bloodstream for example. The next step
in this study is to test whether C. albicans has retained the ability to target accelerated protein
degradation in response to glucose.
Next, the reverse cloning was done by replacing the S. cerevisiae ICL1 ORF in S. cerevisiae with
a Myc3-tagged C. albicans ICL1 ORF. The aim was to test whether the CaIcl1 protein was
destabilised by glucose when expressed in S. cerevisiae. This revealed that the CaIcl1 protein
was not destabilised in response to glucose when expressed in S. cerevisiae. This indicated that
the C. albicans Icl1 protein has lost the signal that triggers destabilisation in response to glucose.
The S. cerevisiae Fbp1 protein is destabilised by glucose via ubiquitination [64]. Therefore, we
reasoned that the CaIcl1 protein might have lost ubiquitination signals, which could account
for the stability of the CaIcl1 protein in S. cerevisiae following glucose addition. Indeed, a
bioinformatic analysis revealed that while ScIcl1 carries ubiquitination sites, CaIcl1 does not.
To test whether ubiquitination might play a role in glucose-accelerated protein degradation
in C. albicans, the impact of UBI4 inactivation upon ScIcl1 degradation was tested. Interestingly,
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inactivation of the polyubiquitin gene slowed ScIcl1 degradation in C. albicans in response to
glucose. This was consistent with the idea that ubiquitination contributes to glucose-acceler‐
ated protein degradation in C. albicans.
If this was the case, the addition of a ubiquitination signal should confer glucose-accelerated
degradation upon the stable CaIcl1 protein. This was tested, showing that a carboxyl-terminal
ScIcl1 ubiquitination signal was sufficient to trigger the rapid degradation of CaIcl1 following
glucose addition to C. albicans cells [63].
Finally, direct biochemical evidence for the involvement of ubiquitination in glucose-acceler‐
ated protein degradation in C. albicans was obtained by showing that ubiquitin co-immuno‐
precipitated with the ScIcl1 and CaIcl1-Ubi proteins in C. albicans, but only when cells were
exposed to glucose [63].
In conclusion, C. albicans is capable of destabilising target proteins in response to glucose, and
this destabilisation is mediated by ubiquitination. The lack of ubiquitination sites on the C.
albicans Icl1 and Pck1 proteins probably accounts for the observation that these glyoxylate cycle
and gluconeogenic enzymes are not destabilised by glucose in C. albicans.
5. Conclusion and Future Perspectives
Overall, the topic was to explore the impact of glucose on the assimilation of alternative carbon
sources and catabolite inactivation in C. albicans. To achieve this, the effects of glucose on the
transcriptional and post-transcriptional regulation of key genes and enzymes were studied,
and the molecular mechanisms that trigger protein destabilisation in response to glucose were
examined. These effects were then compared with glucose responses in S. cerevisiae.
Gene expression in both C. albicans and S. cerevisiae is sensitive to glucose. In both yeasts, ICL1
and PCK1 mRNA expression levels were down-regulated in response to glucose. This
confirmed the previous microarray studies in S. cerevisiae [54] and in C. albicans [55].
ICL1 and PCK1 are involved in the utilisation of alternative carbon sources such as organic and
fatty acids, and these genes are repressed by glucose in S. cerevisiae. Indeed gluconeogenic and
glyoxylate cycle genes have been shown to be repressed by glucose concentrations as low as
0.01% in S. cerevisiae [54]. Similarly, C. albicans genes involved in central carbon metabolism
respond rapidly to the addition of glucose. Indeed the PCK1 and ICL1 genes have been shown
to be repressed by glucose at levels as low as 0.1% [55]. These observations imply that the
utilisation of alternative carbon sources could be repressed by glucose in C. albicans. Given that
if C. albicans genes involved in the utilisation of alternative carbon sources are glucose- regulated
in a similar fashion to those in S. cerevisiae, then it might be expected that these genes would be
repressed during systemic infections. However, during phagocytosis by macrophages, C.
albicans cells appear to up-regulate the glyoxylate cycle, as the expression of the isocitrate lyase
(ICL1) and malate synthase (MLS1) genes is induced [80]. The same applies to the gluconeogen‐
ic gene, PCK1 [34]. Furthermore both ICL1 and PCK1 appear to be expressed in some C. albicans
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cells during systemic kidney infections [34]. Various studies have shown that genes involved
in gluconeogenic and glyoxylate cycle contribute to fungal virulence [34, 62, 79].
C. albicans often occupies niches that contain complex mixtures of carbon sources. Our initial
working hypothesis, therefore, was that C. albicans might exploit many of these diverse carbon
sources rather than focussing on glucose alone. Therefore, the tight glucose repression of the
PCK1 and ICL1 genes seemed somewhat surprising [54, 55, 76] because this was inconsistent
with our working hypothesis. Our subsequent discovery that the Pck1 and Icl1 enzymes were
not destabilised by glucose was more consistent with this working hypothesis. Catabolite
inactivation – the rapid degradation of specific enzymes following glucose exposure – is a well-
defined phenomenon in S. cerevisiae. In the yeast, the gluconeogenic enzyme Fbp1 is rapidly
degraded when cells are shifted from media with poor carbon sources to rich media containing
glucose [59]. Consistent with this, in this project it was found that both the Icl1 and Pck1
proteins were rapidly degraded in S. cerevisiae in response to glucose. This was the case when
cells were pre-grown on lactic acid or oleic acid. In contrast, the C. albicans Icl1 and Pck1
proteins were not destabilised in response to glucose when cells were exposed to glucose. The
stability of the CaIcl1 and CaPck1 enzymes in the presence of glucose suggested that C.
albicans might be capable of continuing to utilise alternative carbon sources even when glucose
became available. This suggestion was more consistent with our working hypothesis that C.
albicans has evolved to utilise carbon sources simultaneously in complex niches.
To examine this, the impact of glucose on the ability of C. albicans to assimilate radiolabelled
lactic acid or oleic acid was tested and compared with that of S. cerevisiae. These incorporation
studies confirmed the divergent behaviour of these yeasts with respect to their patterns of
carbon assimilation. In S. cerevisiae, the assimilation of lactic and oleic acid was repressed by
glucose and subsequent growth was reliant on glucose. In contrast, in C. albicans, the utilisation
of lactic and oleic acid was not repressed by glucose. Hence, the utilisation of alternative carbon
sources by C. albicans was not repressed by glucose, and thus the subsequent growth of this
pathogen was supported by assimilating both glucose and alternative carbon sources [63].
In summary, both C. albicans and S. cerevisiae displayed similar responses to glucose at the
transcriptional level, but their responses at post-transcriptional and metabolic levels differed
significantly. Therefore, C. albicans can assimilate both glucose and alternative carbon sources
at the same time, whereas S. cerevisiae is not able to do so (Fig. 1). This is predicted to play a
significant role in the growth of this fungus during infection in the human host [41]. This could
be tested by reprogramming the Icl1 and Pck1 enzymes to be glucose- sensitive in C. albi‐
cans. The prediction is that this engineered C. albicans strain would grow less well on mixed
carbon sources containing glucose, and hence would display attenuated virulence. Additional
experiments that could be carried should test the impact of carbon sources other than glucose,
(such as lactose, galactose or fructose) [Ting and Sandai, unpublished] on the stability of
gluconeogenic and glyoxylate cycle enzymes in C. albicans. Fructose, lactose and galactose are
commonly found in the diet, and significant differences are thought to exist between C.
albicans and S. cerevisiae with regard to the regulation of galactose utilisation [81, 82].
Another additional experiment could involve the broad screening of central metabolic
enzymes in C. albicans for consensus ubiquitination target sites, beyond the preliminary screen
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performed here. This would help to extend the predicted impact of glucose on central
metabolic pathways. This preliminary bioinformatic screen of gluconeogenic and glyoxylate
cycle enzymes has indicated that the S. cerevisiae Icl1, Fbp1, Eno1 and Pck1 proteins carry high
confidence ubiquitination sites (Fig. 2). Previous studies have shown that ScFbp1 is catabolite
inactivated in a glucose-dependent manner via ubiqutination and proteasomal degradation
[59]. In contrast, in C. albicans, only Eno1 carries a high confidence ubiquitination site. This
bioinformatic analysis is consistent with the suggestion that gluconeogenesis and the glyoxy‐
late cycle are insensitive to glucose or at least glucose stimulated, ubiquitin-mediated protein
degradation in C. albicans [63].
The next main step in this project involved testing whether C. albicans has retained the
molecular capability of destabilising target proteins in response to glucose. Examinations of
Icl1 protein levels in both S. cerevisiae and C. albicans revealed that while Icl1 is rapidly degraded
in response to glucose in S. cerevisiae, Icl1 remains stable in C. albicans. To test whether the C.
albicans Icl1 protein has lost the signal that triggers destabilisation in response to glucose, the
C. albicans ICL1 ORF was expressed in S. cerevisiae. Interestingly, the C. albicans Icl1 protein was
not destabilised in response to glucose when it was expressed in S. cerevisiae. This was
consistent with the idea that the C. albicans Icl1 protein has lost the signal required to trigger
glucose-accelerated degradation [66].
The next step is to test whether C. albicans has retained the ability to degrade target proteins
in response to glucose. To investigate this, the tagged S. cerevisiae Icl1 protein was expressed
in C. albicans. This tagged S. cerevisiae Icl1 protein was rapidly degraded when the C. albicans
cells were exposed to glucose. This indicated that C. albicans has retained the molecular
apparatus that mediates glucose-accelerated protein decay (or “catabolite inactivation”).
What apparatus mediates this glucose-accelerated degradation? In S. cerevisiae, ubiquitination
plays an important role in the rapid proteasome-mediated degradation of Fbp1 in response to
glucose [57]. Therefore, the amino acid sequences of ScIcl1 and CaIcl1 were screened for
consensus ubiquitination sites. This revealed that while the ScIcl1 sequence has strong
ubiquitination sites, the CaIcl1 sequence does not (Fig. 3). Therefore, to examine whether
ubiquitination plays a role in glucose-accelerated protein degradation in C. albicans, the impact
of a polyubiquitin (ubi4/ubi4) null mutation [74] on the degradation of ScIcl1 in C. albicans was
tested. The tagged ScICL1 ORF was expressed in this C. albicans ubi4/ubi4 mutant and its decay
rate was measured in the presence and absence of glucose. Compared to the controls, the
degradation of ScIcl1 was relatively slow in the C. albicans ubi4/ubi4 mutant. This suggested
that ubiquitination plays a role in glucose-accelerated protein degradation in C. albicans.
To test this further, we investigated the effects of introducing a S. cerevisiae ubiquitination site
on to the carboxyl-terminus of the stable CaIcl1 protein. This CaIcl1-Ubi protein was destabi‐
lised in response to glucose in C. albicans (Fig. 3). This confirmed that ubiquitination plays a
key role in glucose-accelerated protein degradation in C. albicans. It is also confirmed that C.
albicans has retained the molecular apparatus that destabilises target proteins in response to
glucose. In summary, C. albicans cells have retained the molecular apparatus that degrades
target proteins in response to glucose, but CaIcl1 has lost the signal that triggers this destabi‐
lisation. As a result, the stability of CaIcl1 enzyme in the presence of glucose allows C.
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albicans cells to continue to use alternative carbon sources such as lactic and oleic acid rather
than switching to glycolysis.
What is the apparatus required to trigger glucose accelerated decay? Ubiquitin- mediated
protein degradation occurs via the proteasome [83]. This is a conserved molecular machine
comprised of numerous protein subunits. Proteins are targeted to the proteasome via ubiqui‐
tination, which involves several steps (Fig. 4). Ubiquitin is activated in a two-step process
involving the E1 and E2 enzymes and the hydrolysis of ATP. The primed ubiquitin molecule,
once attached to an E2 enzyme via a thioester linkage, is then ligated to the target protein via
an E3 ligase which provides the substrate specificity. A previous PhD student in the Aberdeen
Fungal Group Laboratory [84] has already shown that proteasomal subunits are highly
conserved across the fungal kingdom and are conserved in C. albicans (Fig. 4). Furthermore,
E1, E2 and E3 enzymes are conserved in C. albicans (Fig 4) [85], which are consistent with the
ubiquitination apparatus being retained in this pathogen. Presumably, the inactivation of
components of this system could block glucose-accelerated protein degradation in C. albicans.
In S. cerevisiae, Ubc8 appears to be the ubiquitin-conjugating enzyme involved in glucose-
accelerated protein degradation. Ubc8 has been described as a ubiquitin-conjugating enzyme
that negatively regulates gluconeogenesis by mediating the glucose-induced ubiquitination of
Fbp1 [57, 64, 85, 86]. Interestingly the Ubc8 protein appears to be conserved in C. albicans [87].
Additional ubiquitin-conjugating enzymes exist in C. albicans, such as Ubc4 and Ubc6, and
these might also be involved. However, all these UBC genes remain uncharacterised in C.
albicans, and therefore it is not yet known whether these genes play a role in glucose-accelerated
protein degradation. Interestingly however, UBC8 is the only ubiquitin-related gene that is
up-regulated at the transcriptional level following glucose exposure in C. albicans (Table 1).
Therefore, Ubc8 is an excellent candidate for the ubiquitin-conjugating enzyme that mediates
glucose-accelerated protein degradation in C. albicans. Clearly, a future experiment that could
be carried out would be to create a C. albicans ubc8/ubc8 mutant and to test whether this
mutation blocks glucose-accelerated protein degradation in C. albicans. Other UBC genes might
also be inactivated to test the possibility that they are not involved in glucose-accelerated
protein degradation [63].
These findings are relevant to our understanding of C. albicans growth and survival in the host,
and hence to C. albicans pathogenicity. C. albicans persists as commensal during colonisation
in the healthy human GI tract where monosaccharides (such as glucose, fructose and galactose)
and disaccharides (such as sucrose and lactose) can be abundant [88]. These sugars probably
help to sustain the fungus, for example, during the first 6 months of a host’s life when new
born infants consume milk and hence lactose [89]. Both disaccharides and monosaccharides
may supply a carbon-rich environment for microbes such as C. albicans, and they are also
absorbed into the bloodstream [82]. However, during systemic infections C. albicans cells
invade the bloodstream and often internal organs such as kidney. Glucose is present in the
bloodstream but appears to become limited in systemic microenvironments that are colonised
during infection of organs. At this point, the fungal cells probably switch to gluconeogenesis
and glyoxylate cycle metabolism to utilise the available alternative carbon sources [34]. Also,
during phagocytosis, by macrophages and neutrophils, C. albicans cells switch to the assimi‐
lation of alternative carbon sources, activating genes such as ICL1 [34, 62, 79, 89] that are
required for full pathogenicity [34, 79]. It would appear from the findings in this chapter, that
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C. albicans has evolved in such a manner that this fungus can continue to assimilate these
alternative carbon sources, even after exposure to glucose. The presumption is that this ability
to use several of carbon sources in these complex and carbon-rich microenvironments
contributes to the growth and pathogenicity of C. albicans in these microenvironments. Possibly
the greatest challenge for the future is to elucidate exactly what carbon sources individual C.
albicans cells assimilate in vivo during commensalism, mucosal infection and systemic candi‐
diasis and to elucidate the contribution of transcriptional and post-transcriptional control
mechanisms to this regulation.
This carbon metabolism of C. albicans might be investigated further by examining the ability
of mutant C. albicans cells that carry the ICL1-ubi allele to grow and assimilate carbon in vivo.
These C. albicans cells express Icl1 that is destabilised by glucose because of the addition of the
carboxyl-terminal ubiquitination site. In principle, Icl1 would be degraded and cells no longer
able to metabolise via the glyoxylate cycle following glucose addition. As a result, those cells
would presumably be less able to course infections and would be less able to compete for
available nutrients against other microorganisms such as endogenous bacteria in the GI tract
compared to their wild type. It is likely to show less successful colonisation, virulence and
fitness due to this defect in its ability to assimilate both glucose and alternative carbon sources
at the same time [63].
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Figure 1. Proposed model of the impact of glucose on the assimilation of alternative carbon sources by S. cerevisiae and
C. albicans. In C. albicans and S. cerevisiae transcription of both ICL1 and PCK1 are repressed by glucose. However, their
regulation at post-transcriptional levels and metabolism diverge significantly. The S. cerevisiae Icl1 and Pck1 proteins
are rapidly destabilised in response to glucose and the assimilation of alternative carbon sources is repressed by glu‐
cose. In contrast, in C. albicans the Icl1 and Pck1 proteins decay slowly in response to glucose and continue to assimi‐
late both glucose and alternative carbon sources at the same time.
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In addition, it would be interesting to conduct further investigations of the impact of other
carbon sources such as galactose, fructose, sucrose, fatty acid and amino acid on carbon
assimilation in C. albicans. For example galactose might also trigger glucose-like repression in
C. albicans [82]. The behaviour of C. albicans towards other carbon sources differs from S.
cerevisiae. It would be interesting to define the effects of these carbon sources on the levels and
activities of glycolytic, gluconeogenic, glyoxylate cycle and fatty acid β-oxidation enzymes.
Which other carbon sources trigger the ubiquitination-mediated degradation of these proteins
in C. albicans? How do these mechanisms affect the ability of C. albicans to assimilate lipid,
carbohydrate, protein and other organic acids in their human host during commensalism and
infection? Such studies will provide a more complete physiological understanding of C.































































































































S. CEREVISIAE C. ALBICANS
Figure 2. Bioinformatic prediction of ubiquitination sites in glycolytic, gluconeogenic and glyoxylate cycle enzymes
from S. cerevisiae and C. albicans. Icl1, Pck1, Eno1 and Fbp1 were examined. Those carrying high confidence ubiquitina‐
tion sites are highlighted in red.
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Figure 3. Role of ubiquitin-mediated protein degradation in enzyme destabilisation in C. albicans in response to
glucose. Bioinformatics comparison of CaIcl1 and ScIcl1 reveals a lack of putative ubiquitination target in CaIcl1. Intro‐
duction of carboxyl-terminal ScUbi-site in CaIcl1 plus Myc-tagging protein and testing the impact of glucose on the
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Figure 4. Protein conservation in the proteasome. Each protein is colour-coded according to its mean distance to
ScREF scores (scale bottom right: high ScREF scores represent low sequence conservation). Each subunit of the actual
machine (20S core particle and 19S cap) has been colour -coded based on the mean of the mean distance to ScREF val‐
ues for the proteins that form it in all species. Rpn13 (ScREF distance = 82) is not included in the picture. Ubiquitin-
related enzymes have been reviewed by Hochstrasser (1996), and protein component of the machine was identified
based on the review by Sharon and co-workers (2006). In the ubiquitin-ligating enzymes, except for the Ubr1 and Ubr2
enzymes, all the others are hect-domain proteins [84].
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